---
title: "VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trials"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290604087.md"
description: "VS-7375 demonstrated broad anti-tumor activity and a favorable safety profile in advanced KRAS G12D-mutated solid tumors, with promising efficacy in pancreatic, colorectal, and lung cancers. Multiple Phase 2 trials are underway, and a collaboration will explore combination strategies.Original document: Verastem, Inc. [VSTM] Press release — Jun. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-06-23T20:12:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290604087.md)
  - [en](https://longbridge.com/en/news/290604087.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290604087.md)
---

# VSTM: VS-7375 shows promising efficacy and safety in KRAS G12D-mutated cancers, advancing to Phase 2 trials

VS-7375 demonstrated broad anti-tumor activity and a favorable safety profile in advanced KRAS G12D-mutated solid tumors, with promising efficacy in pancreatic, colorectal, and lung cancers. Multiple Phase 2 trials are underway, and a collaboration will explore combination strategies.

Original document: Verastem, Inc. \[VSTM\] Press release — Jun. 23 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [VSTM.US](https://longbridge.com/en/quote/VSTM.US.md)

## Related News & Research

- [Verastem Advances VS-7375 Into Phase 2 Pancreatic Trial](https://longbridge.com/en/news/290061220.md)
- [Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer](https://longbridge.com/en/news/290083508.md)
- [Sam Altman said AI hasn't led to 4-hour workweeks because people are competitive](https://longbridge.com/en/news/293883472.md)
- [Surgeon highlights AI breakthrough that could spot cancer before doctors](https://longbridge.com/en/news/293634215.md)
- [Calidi Biotherapeutics targets Q1 2027 clinic entry for CLD-401 cancer program](https://longbridge.com/en/news/293929420.md)